Abstract: A method of combating rheumatoid arthritis, comprising administering to a human subject in need thereof, an effective oral dose of a probiotic composition in an oral dose form including, as the only bacterial species therein, the bacterial species of Bacillus subtilis, Bacillus coagulans, and Enterococcus faecium. The initial occurrence, and progress of remission of the rheumatoid arthritis condition incident to such probiotic therapy, may be established and monitored by assay of rheumatoid factor and/or anti-CCP antibodies present in a blood sample of the human subject.
Abstract: The invention discloses a composition comprising at least one N-acetyl-lactosamine, at least one sialylated oligosaccharide and at least one fucosylated oligosaccharide, for use in the prevention and/or treatment of skin conditions and skin diseases. Preferably said composition is a starter infant formula. Said skin disease is in particular atopic dermatitis.
Abstract: The present invention concerns the reduction of gastro-intestinal methanogenesis in ruminants with the aid of agents that compete for the hydrogen atoms required by methanogens during normal fermentation of ingested feed. The invention in one aspect resides in the findings that both nitrate reductive pathways as well as sulphate reductive pathways outcompete gastro-intestinal methanogenesis in ruminants and, that the methanogenesis reducing effects of nitrate and sulphate are completely additive. At the same time the combined administration of nitrate and sulphate was found to be fully effective to avoid or mitigate the potential problems of nitrite intoxication normally encountered when using nitrate alone, which effect is further enhanced, where necessary, by the addition of a nitrite reducing probiotic micoroorganism.
Type:
Grant
Filed:
July 23, 2010
Date of Patent:
July 8, 2014
Inventors:
Hindrik Bene Perdok, Sander Martijn Van Zijderveld, John Richard Newbold, Rob Bernard Anton Hulshof, David Deswysen, Walter Jan Jozef Gerrits, Jan Dijkstra, Ronald Alfred Leng
Abstract: The present invention provides methods for treating retinal disorders using a nutraceutical composition comprising lutein and zeaxanthin. Methods for treating vitreomacular traction disorder and related disorders are disclosed.
Abstract: The present invention relates to a novel wild-type Lactococcus lactis subsp. cremoris bacteria strain with increased vitamin K2 production and mutants and variants thereof and methods for preparation of a fermented food or feed product enriched in vitamin K2 and a vitamin K enriched edible product for amelioration and/or prevention of vitamin K deficiency. The present invention also relates to the fermented food or feed product and the edible product obtainable by the methods herein and to the wild-type Lactococcus lactis subsp. cremoris bacteria strain for use in treatment and/or prevention of vitamin K deficiency in a mammal, such as a human.
Type:
Grant
Filed:
August 11, 2011
Date of Patent:
July 1, 2014
Assignee:
Chr. Hansen A/S
Inventors:
Christel Garrigues, Martin Bastian Pedersen
Abstract: Prosthetic apparatuses with probiotic microorganisms to control colonization of pathogenic bacteria are disclosed. The prosthetic apparatus may include a first portion having a first mating surface, a second portion having a second mating surface that conforms to the first mating surface, and at least one strain of probiotic microorganisms retained between the first and second mating surfaces prior to implantation of the prosthetic apparatus.
Abstract: This disclosure relates to enhancing growth and/or activity of lactobacilli using a prebiotic formulation which includes iso-malto oligosaccharides and ?-galactosidase; and to enhancing growth and/or activity of bifidobacteria using a prebiotic formulation which includes iso-malto oligosaccharides and ?-glucanase. Other combinations of fibers and enzymes are described below which also stimulate growth and activity of lactobacilli or bifidobacteria. These combinations of enzymes and prebiotics can be taken separately or added to foods, including desserts.
Abstract: The current invention is based upon administration of a probiotic, B. Lactis NCC2818 to healthy young mammals during the critical weaning period (in infants this period is usually from about 3 months to about 12, 18 or 24 months old), so as to accelerate the young mammal's adaptation to new food. The effectiveness of the invention is evidenced herein by morphological and immunological changes observed in a piglet animal model of weaning. Thus, administration of the probiotic according to the invention had a prophylactic effect, preventing the severe discomfort and pathological states associated with the introduction to novel foods during the weaning period.
Type:
Application
Filed:
July 11, 2012
Publication date:
June 19, 2014
Applicant:
NESTEC S.A.
Inventors:
Swantje Duncker, Marie Lewis, Annick Mercenier, Anurag Singh, Michael Bailey
Abstract: The invention relates to a zinc-enriched biomass comprising living or subsequently killed micro-organisms, selected from the group consisting of Streptococcus thermophilus and Bifidobacterium animalis subsp. lactis and combinations thereof, a method for the manufacture of said zinc-enriched biomass, as well as food preparations, nutraceutic products, functional foods, cosmetic and cosmeceutic products, and food supplements, comprising the said biomass. Furthermore, new micro-organism strains are described which are able to concentrate zinc within the cell in very high amounts and therefore are particularly suitable for use in the method of the invention.
Abstract: A protein-rich nutritional food product composed of a probiotic and an edible isolated protein. The probiotic component may comprise Lactobacillus, Bacillus, Streptococcus Bifidobacteria, Saccharomyces or Leuconostoc. The isolated protein may comprise whey proteins, whey growth factor extract, glutamine peptide, egg albumen, soy proteins, or caseinates. This nutritional composition can be in the form of a food product, dietary supplement, or medical food which, upon ingestion, will promote a healthy intestinal microenvironment, provide a source of protein, and assist in the elimination of nitrogenous waste products that can build up in concentration in the circulating blood. Increased concentrations of the wastes are known to exert a negative impact on an individual's physiology and contribute to a decreased sense of well-being and general malaise. Methods for removing nitrogenous waste products from the blood and ameliorating renal failure using the nutritional product of the invention are also provided.
Abstract: The present invention discloses an “Improved Oral Targetted Drug Delivery System (O-TDDS)” particularly suited for delivery of drugs having activity against the diseases located in the colon e.g. colon cancer, ulcerative colitis, protozoal infections etc. The system comprises two elements or parts viz. microspheres (drug+natural polymers such as guar gum or xanthan gum) and probiotics. Both the elements are packed together in a single, pharmaceutically acceptable oral dosage form such as a capsule. The system offers distinct advantages of drug delivery without undesirable side-effects of diarrhea, nausea or vomiting commonly encountered in case of anti-cancer drugs such as 5-Fluorouracil.
Abstract: New Lactococcus lactis strains, NRRL B-50571 and NRRL B-50572, and a bacterial preparation containing the same, have the ability to produce bioactive peptides that reduce blood pressure, lower LDL-cholesterol (bad cholesterol) and present antioxidant properties for better cardiovascular health. These biologically active peptides may be produced within the food for the production of a food product, such as a functional food, or they may be produced from protein sources and subsequently added to a food as part of the formulation or as part of a food supplement or a pharmaceutical preparation.
Type:
Application
Filed:
September 27, 2012
Publication date:
June 5, 2014
Applicants:
CENTRO DE INVESTIGACION EN ALIMENTACION Y DESARROLLO, A.C. (CIAD)
Inventors:
BELINDA VALLEJO GALLAND, AARÓN FERNANDO GONZÁLEZ CÓRDOVA, JOSÉ CARLOS RODRÍGUEZ FIGUEROA
Abstract: According to the present invention, an anti-allergic agent is provided which includes a polysaccharide comprising galactose, glucose and rhamnose as constituents, or includes a microorganism belonging to a genus Bifidobacterium and extracellularly producing the polysaccharide. The anti-allergic agent of the present invention can be used in oral compositions and compositions for external application, and is suitable for use in products such as food products, pharmaceutical products, and cosmetics.
Abstract: A bacillus composition characterized by fast germination and outgrowth in bile salts (simulated gut environment) and by high-level secretion of essential amino acid. The bacillus composition may be used as supplement in animal feed where it has a probiotic (health promoting) effect and increases the digestion and availability of nutrients from animal feeds.
Type:
Grant
Filed:
December 16, 2009
Date of Patent:
June 3, 2014
Assignee:
Chr. Hansen A/S
Inventors:
Mette Dines Cantor, Patrick Derkx, Inge Knap, Ane Knarreborg, Thomas Dyrmann Leser, Lund Bente
Abstract: The present invention provides compositions that include an extract of human feces, and methods for using such compositions, including methods for replacing or supplementing or modifying a subject's colon microbiota, and methods for treating a disease, pathological condition, and/or iatrogenic condition of the colon.
Type:
Application
Filed:
March 9, 2012
Publication date:
May 29, 2014
Applicant:
REGENTS OF THE UNIVERSITY OF MINNESOTA
Inventors:
Michael J. Sadowsky, Alexander Khoruts, Alexa R. Weingarden, Matthew J. Hamilton
Abstract: A particle is disclosed. The particle comprising: (i) at least one inner core which comprises a solid matrix of nutrients for microorganism growth; (ii) an inner membrane being fabricated from a water-soluble polymer, the inner membrane surrounding the inner core and a population of dried microorganisms; and (iii) an outer porous membrane surrounding the inner membrane, the outer porous membrane being insoluble in water. Methods of generating same, propagating microorganisms within and uses of same are also disclosed.
Abstract: Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.
Type:
Application
Filed:
November 26, 2013
Publication date:
May 29, 2014
Applicant:
Seres Health, Inc.
Inventors:
Matthew R. Henn, Geoffrey von Maltzahn, Anthony Mario D'Onofrio, Kevin Daniel Litcofsky, David A. Berry, David N. Cook, Noubar B. Afeyan, John Grant Aunins
Abstract: The present invention relates inter alia to the use of a combination of a vaccine against Lawsonia intracellularis and an anti-Lawsonia antibiotic for the prevention or reduction of early, preferably fulminant Lawsonia intracellularis infections. The present invention relates particularly to the use of a live Lawsonia intracellularis vaccine in conjunction with an antibiotic that is effective against Lawsonia intracellularis, for the avoidance or reduction of early Lawsonia intracellularis infections in animals.
Abstract: The invention relates to a composition comprising a combination of an elder extract (Sambucus nigra) and a strain of L. paracasei, L. casei, L. bulgaricus or S. thermophilus, intended for stimulating immunity and/or promoting an anti-infectious and/or anti-inflammatory response.
Type:
Grant
Filed:
October 16, 2009
Date of Patent:
May 27, 2014
Assignees:
Pierre Fabre Medicament, Compagnie Gervais Danone
Abstract: The present invention provides a method for producing a cytosine deaminase (CD)-expressing, 5-fluorouracil (5-FU)-resistant microorganism which can grow in anaerobic tumor tissues, can express CD, and has a resistance to 5-FU at a concentration that is at least effective for antitumor activity. More specifically, the method is a method (A) comprising performing subculture or acclimation culture of a CD-expressing microorganism which can grow in anaerobic tumor tissues, in the presence of 5-fluorocytosine (5-FC), or a method (B) comprising (1) performing subculture or acclimation culture of a microorganism which can grow in anaerobic tumor tissues and does not express CD, in the presence of 5-FU to produce a 5-FU-resistant microorganism and (2) transforming the 5-FU-resistant microorganism by introducing a CD gene. The present invention also provides the CD-expressing, 5-FU-resistant microorganism and a pharmaceutical composition comprising the microorganism.
Type:
Grant
Filed:
April 4, 2006
Date of Patent:
May 27, 2014
Assignee:
Anaeropharma Science Inc.
Inventors:
Yoshinori Hamaji, Minoru Fujimori, Jun Amano, Shun'ichiro Taniguchi
Abstract: Schistosomiasis mansoni is caused by flukes called Schistosoma(es) that enters the human body through the skin in Schistosoma infested waters. The Schistosomes travel from the skin into human blood vessels where they mate, produce antigen containing eggs that travel from the blood vessels into the small intestines, where they are released in the human feces. Male and female Schistosome mates in human blood vessels, male Schistosomes secrete a protein called TGR ? protein to the Trk receptor sites on the females Schistosomes membranes. The process stimulates the formation of chemical SmInAct in female Schistosomes, a chemical necessary for the female Schistosomes to produce eggs. This novel technique describes new methods to inhibit Trk receptor sites on female Schistosome membranes using Trk inhibitor agent to prevent TGR ? proteins from binding to the Trk receptor sites. Thus, preventing SmInAct from being created in female Schistosomes, preventing production of eggs and Schistosomiasis.
Abstract: The invention relates to a composition which, depending on the user, may be taken as a nutritional, dietetic or strictly therapeutic preparation, comprising as its active substance alkaline sphingomyelinase which is capable of preventing or treating various pathological conditions including cancerous processes, inflammatory processes of the intestine, hypercholesterolaemia and infections with Helicobacter pylori.
Abstract: The present invention provides a novel bacterial cell composition which comprises cells of Butyrivibrio fibrisolvens having the ability to produce butyric acid, a cultured material thereof or an extract thereof, and a method for inhibiting carcinogenesis, a method for immunostimulating, a method for preventing or treating a pathogen, a method for preventing or treating an inflammatory bowel disease and a method for preventing or treating an allergic disease, which use the same.
Abstract: A biological soil nutrient system that combines beneficial soil fungi and bacteria in a growth promoting nutrient medium, embedded in an inorganic porous ceramic particle for direct delivery during soil aerification to the rhizosphere of adventitious plants, including sports turf, landscape and agricultural applications.
Abstract: An object of the present invention is to provide a means for imparting resistance against pathogenic fungal, pathogenic bacterial, or pathogenic viral disease to agriculturally useful plants. The present invention relates to a bacterium belonging to the genus Azospirillum or the genus Herbaspirillum capable of imparting resistance against pathogenic fungal, pathogenic bacterial, or pathogenic viral disease to a host plant by living symbiotically within the plant, a method for controlling plant disease using the bacteria, and plants produced by such method.
Abstract: The invention provides compositions and methods for preserving lean body mass during weight loss in an animal. The methods comprise administering OEA to the animals, preferably in amounts of from about 0.01 to about 1000 mg/kg/day.
Abstract: A method of treating uterine infections in a female bovine includes the step of, prior to parturition, intravaginally administering the female bovine with one or more bacterial strains such as Lactobacillus sakei FUA 3089, Pediococcus acidilactici FUA 3140, and Pediococcus acidilactici FUA 3138, effective for treating pathogenic microorganisms associated with postpartum infection of the uterus of female bovines.
Abstract: The present invention relates to compositions and methods for preventing and treating periodontitis and other conditions. In particular, the present invention relates to oral bacteria for use in treating and preventing diseases and conditions.
Type:
Application
Filed:
March 2, 2012
Publication date:
May 8, 2014
Applicants:
TUFTS MEDICAL CENTER, TUFTS UNIVERSITY
Inventors:
Linden Hu, Brian A. Klein, Elizabeth Tenorio
Abstract: Selected bacterial strains belonging to the genus Bifidobacterium for use in the treatment of hypercholesterolaemia are described. In particular, a food composition or supplement product or medical device or pharmaceutical composition has said bacterial strains in association with sterols or phytosterols and/or stanols or phytostanols and/or glucomannan and/or konjac gum and/or prebiotic fibres and/or fermented red rice and/or betaglucans from oats, oat bran, barley, barley bran and/or aloe arborescens gel in lyophilized form.
Type:
Application
Filed:
May 9, 2012
Publication date:
May 8, 2014
Inventors:
Giovanni Mogna, Gian Paolo Strozzi, Luca Mogna
Abstract: Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, wherein A is a 6-membered aromatic ring containing carbon atoms and 0-3 nitrogen atoms as ring members, said ring optionally substituted with 1-5 substituents independently selected from R2; R1 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 alkylcycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with one or more substituents independently selected from R21; R21 is independently H, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, CN or NO2; and Q is as defined in the disclosure.
Type:
Application
Filed:
January 6, 2014
Publication date:
May 8, 2014
Applicant:
E.I. du Pont de Nemours and Company
Inventors:
George Philip Lahm, Ty Wagerle, Ming Xu
Abstract: The use of probiotic bacteria in the manufacture of a composition for administration to a woman in at least the third trimester of pregnancy for prevention of gestational diabetes, normalizing plasma glucose concentration and/or increasing insulin sensitivity.
Type:
Application
Filed:
January 10, 2014
Publication date:
May 8, 2014
Applicant:
NESTEC S.A.
Inventors:
Seppo Salminen, Erika Isolauri, Kirsi Laitinen
Abstract: This invention provides methods and compositions for producing reduced cholesterol animal foodstuffs and products by feeding livestock and other food-producing animals with feed supplemented with microbial cultures containing hypocholesterolemic compounds produced by microorganisms comprising said microbial cultures. The invention provides low cholesterol poultry, eggs, meat, whole milk, and dairy products.
Type:
Grant
Filed:
May 29, 2002
Date of Patent:
May 6, 2014
Assignee:
Jinis Biopharmaceuticals Co.
Inventors:
Seong-Tshool Hong, Hyeon-Jin Kim, Dae-Kwon Lee, Won-Young Yang
Abstract: Provided are bioactive compounds and metabolites derived from Chromobacterium species culture responsible for controlling pests, compositions containing these compounds, methods for obtaining these compounds and methods of using these compounds and compositions for controlling pests.
Abstract: The present invention relates to a method for decreasing borborygmi in a subject by administering a probiotic, preferably a bacteria of the Bifidobacterium genus, said method being on one aspect of the invention a non therapeutic method.
Type:
Grant
Filed:
May 26, 2009
Date of Patent:
May 6, 2014
Assignee:
Compagnie Gervais Danone
Inventors:
Denis Guyonnet, Stefan Jakob, Armelle Schlumberger
Abstract: Antibiotic-associated enteric pathogens are shown to increase in mucosal carbohydrate availability that occur upon disruption of the competitive ecosystem. Transient post-antibiotic increase in monosaccharides liberated by the resident microbiota from host mucus provides a window of opportunity for these pathogens to expand to densities sufficient to induce self-promoting host inflammation.
Abstract: Probiotic Bifidobacterium strain AH1205 or mutants or variants thereof are immunomodulatory following oral consumption and are useful in the prophylaxis and/or treatment of inflammatory activity such as undesirable gastrointestinal inflammatory activity for example inflammatory bowel disease.
Type:
Grant
Filed:
March 28, 2008
Date of Patent:
April 29, 2014
Assignee:
Alimentary Health Limited
Inventors:
John MacSharry, Liam O'Mahony, David O'Sullivan, Barry Kiely
Abstract: At least one phytosphingosine salicylate derivative and at least one lysate of at least one microorganism of the genus Bifidobacterium. Composition, combination. Use, including cosmetic use for reinforcing the repair and regeneration capacity of an epithelium, especially an epidermis, in particular an aged epidermis.
Type:
Grant
Filed:
January 12, 2010
Date of Patent:
April 29, 2014
Assignee:
L'Oreal
Inventors:
David Amar, Bruno Bernard, Dominique Bernard, Isabelle Castiel
Abstract: The present invention relates to a method of treating or prophlaxis of a respiratory tract illness in a subject comprising administering to said subject a composition comprising Bifidobacterium lactis BL04 and/or fermentation product of Bifidobacterium lactis BL04 and/or a cell lysate of Bifidobacterium lactis BL04.
Type:
Application
Filed:
June 8, 2012
Publication date:
April 24, 2014
Applicant:
DUPONT NUTRITION BIOSCIENCES APS
Inventors:
David Pyne, Nicholas West, Allan Cripps, Sampo Lahtinen
Abstract: The current invention is directed towards a rapid, reproducible test for the fungal virulence factors and associated affected compounds so that patients at risk for autism, cerebral palsy and other human diseases can be quickly identified, treated and possibly prevented. This includes a multitude of test protocols for both the mycotoxin gliotoxin and its relationship with glutathione- and relates the two molecules by a novel paradigm known as the Glutathione-Gliotoxin Index-(GGI) or Disease-Disorder Susceptibility Index-D/DSI, which indicates the Autism Susceptibility Index-(ASI). One testing device and protocol includes a cellular phone application with modification to test for susceptibility to autism and other disease states.
Abstract: This invention relates to prophylactic and/or therapeutic application of microorganism species that are, for example, administered orally as delayed release formulation designed to release its microbial content to the distal small intestine and/or colon in high quantities and density, which is a “normalized” approach to repopulate the colonic flora as a method of prevention and/or treatment of, for example, Clostridium difficile colitis.
Type:
Application
Filed:
October 22, 2012
Publication date:
April 24, 2014
Applicant:
POLONEZ THERAPEUTICS LLC
Inventors:
Wieslaw J. Bochenek, Michael L. Corrado
Abstract: A method for reducing methane production in a ruminant animal comprising the step of administering to said ruminant animal an effective amount of at least one strain of bacterium of the genus Propionibacterium.
Type:
Application
Filed:
April 26, 2012
Publication date:
April 24, 2014
Applicant:
DUPONT NUTRITION BIOSCIENCES APS
Inventors:
Claudette Berger, Abderzak Lettat, Cecile Martin, Pierre Noziere
Abstract: Nutritional compositions including milk fat globule membrane components (“MFGM”) and at least one nutrient are provided. The milk-derived, bioactive lipids help to modulate conditions typically found in the elderly including, for example, low-grade inflammation, loss of lean body mass, skeletal muscle cell membrane instability, and joint inflammation. The nutrients may include, but are not limited to, whey protein micelles, citrulline, branched chain fatty acids, and a-hydroxycaproic acid (“?-HICA”). Methods for treating an individual having, or at risk of having, a medical condition are also provided.
Abstract: The present invention provides the use of a composition comprising non-digestible oligosaccharide for the manufacture of a composition for enteral administration to an infant delivered via caesarean section.
Abstract: This document provides methods and materials related to Prevotella histicola preparations. For example, Prevotella histicola preparations in the form of an oral medicament or dietary supplement (e.g., a pill, tablet, capsule) are provided. In addition, methods and materials for using a Prevotella histicola preparation provided herein as an anti-inflammatory agent are provided.
Type:
Application
Filed:
November 21, 2013
Publication date:
April 17, 2014
Applicant:
Mayo Foundation for Medical Education and Research
Inventors:
Joseph A. Murray, Eric V. Marietta, Susan H. Barton, Veena Taneja, Ashutosh Mangalam
Abstract: Oral compositions comprising an association of one or of a mixture of phytoestrogens, selective for the estrogen receptor-?, with dietary fibres are described. The compositions thereof can be profitably used for the prophylactic and therapeutic treatment in mammals, including humans, of health conditions characterised by a high risk of onset and recurrence of intestinal adenomas (adenopolyposis coli), and of adenoma's progression to colorectal carcinoma. In presence of pre-cancerous lesions in the colon, characterised by mutations of the APC tumor suppressor and defined as polyps or adenomas, the oral compositions disclosed can be in fact profitably used to reduce the number and volume of polyps, and to prevent their progression to neoplastic transformation, reducing their degree of dysplasia.
Abstract: The invention includes methods and compositions for treating an animal to inhibit the incidence and growth of E. coli O157:H7 and other pathogenic bacteria. The treatment method comprises administering a therapeutically effective amount of Lactobacillus acidophilus or one or a combination of a number of other probiotic bacteria to an animal. An alternative treatment method comprises administering a therapeutically effective amount of a lactic acid producing bacterium such as Lactobacillus acidophilus in combination with a lactate utilizing bacterium such as Propionibacterium freudenreichii.
Abstract: The present invention relates to butyrate producing bacterial strains related to the species Butyncoccus pullicaecorum to be used in the prevention and/or treatment of intestinal health problems. The present invention therefore provides methods and compositions that overcome the problems associated with the currently used methods for administering butyric acid in the treatment of intestinal health problems in humans and/or animals.
Type:
Grant
Filed:
February 22, 2010
Date of Patent:
April 15, 2014
Assignee:
Universiteit Gent
Inventors:
Filip Van Immerseel, Frank Pasmans, Richard Ducatelle, Benedikt Sas, Venessa Eeckhaut, Freddy Haesebrouck
Abstract: The present invention describes a process for the manufacture of a solid composition comprising a microorganism, which process comprises a first step of blending and/or compacting the microorganism with a salt of a medium or long-chain fatty acid to prepare a powderous mixture or compacted granulate, and a second step of providing said powderous mixture or compacted granulate with a coating. The microorganisms are preferably probiotics. The invention also relates to the solid composition obtained by said process and to its use in food.
Type:
Grant
Filed:
May 18, 2006
Date of Patent:
April 15, 2014
Assignee:
DSM IP Assets B.V.
Inventors:
Chyi-Cheng Chen, Bruno H. Leuenberger, Loni Schweikert, Ernst Zedi
Abstract: The invention relates to a composition which, depending on the user, may be taken as a nutritional, dietetic or strictly therapeutic preparation, comprising as its active substance alkaline sphingomyelinase which is capable of preventing or treating various pathological conditions including cancerous processes, inflammatory processes of the intestine, hypercholesterolaemia and infections with Helicobacter pylori.
Abstract: The invention relates to the use of composition comprising free amino acids as a sole source of protein, a fatty acid source comprising long chain polyunsaturated fatty acids, a carbohydrate source comprising digestible and indigestible carbohydrates, and milk protein free Bifidobacteria for treating a person suffering from (a) colic, congestion, runny nose, wheezing, vomiting, diarrhea, bloody stools, mucus in stools, rash, eczema, gastroesophageal reflux, eosinophilic esophagitis or asthma; (b) cow's milk allergy and/or food protein intolerance; and/or (c) infections, wherein the indigestible carbohydrate is selected from a milk protein free source and the total composition is essentially free of intact proteins.
Type:
Grant
Filed:
July 5, 2007
Date of Patent:
April 8, 2014
Assignee:
SHS International
Inventors:
Jane Elizabeth Langford, Ian Sullivan, Catherine Teresa Deering, Sandra Helen Giffen